Mission Bio Funding, Investors & Competitors

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.

BGI Group is a Shenzhen-headquartered global leader in genomics, operating as Shenzhen Huada Gene Technology Co. Ltd. The company delivers DNA sequencing, bioinformatics testing, genetic analysis, agricultural genomics, and proteomics services. With operations centered in China and international labs, it contributed to the Human Genome Project and advances precision medicine worldwide.

Sangon Biotech is a Shanghai-based biotechnology firm specializing in nucleic acid synthesis and molecular biology products. Founded in 2003 as a Sino-foreign joint venture, it manufactures DNA/RNA oligonucleotides, gene synthesis services, peptides, enzymes, reagents, lab consumables, and benchtop instruments. The company operates a production base in Songjiang Industrial Park, serving research institutions and pharmaceutical companies worldwide.

Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.

Element Biosciences is a San Diego-based life sciences company building next-generation DNA sequencing instruments. The AVITI platform delivers high-accuracy reads using avidity sequencing chemistry, reducing costs through improved signal-to-noise ratios in surface chemistry and biochemistry. Launched in 2022, it supports workflows from short-read to long-read applications for genomics research. Element Biosciences serves academic labs, biopharma, and clinical sequencing markets worldwide.

Immunai is a biotechnology company with locations in New York City, San Francisco, and Tel Aviv, mapping the immune system using single-cell genomics and machine learning. The firm profiles hundreds of immune cell types from blood samples via its proprietary database, aiding biomarker discovery for therapeutics in autoimmune diseases and cancer.

Mammoth Biosciences is a biotechnology company, co-founded by CRISPR pioneer Jennifer Doudna, that develops CRISPR-based tools for diagnostics and gene-editing therapeutics. Its platform is built around compact Cas proteins such as Cas14 and Casφ, which the company applies to in vivo gene editing for genetic and infectious diseases as well as decentralized disease detection. Mammoth has partnered with organizations including Regeneron, GSK, and the NIH, and has received government funding to develop COVID-19 testing technology.

GeneMind Biosciences produces third-generation single-molecule gene sequencing systems, delivering advanced tools for clinicians and researchers through ongoing technological breakthroughs.

Inscripta is a Boulder, Colorado-based gene-editing technology company, founded in 2015, that builds tools for genome engineering used in food, fuel, and healthcare applications. Its flagship product, the Onyx platform, is a benchtop system for digital microbial genome engineering that automates identifying genomic pathways, compiling them into libraries, editing them at scale with CRISPR-based tools such as the MAD7 nuclease, and analyzing the resulting effects, all within a single integrated workflow. Early commercial customers have included the University of Liverpool's GeneMill, which uses the platform to provide synthetic biology services to life-sciences and pharmaceutical partners.

Cellanome is a Redwood City-headquartered synthetic biology platform provider. The company integrates microfluidics, sensors, and multi-omics sequencing for single-cell analysis and pathway engineering. Cellanome's system accelerates CRISPR screening by processing 10,000 variants per run. Founded in 2020, it serves early-stage biotechs in the Bay Area.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Clear Labs is a Woburn-based genomics company delivering next-generation sequencing through Clear Dx for pathogen detection in infectious diseases and Clear Safety for food safety contaminants like Salmonella and E. coli. Its platforms support FDA-compliant surveillance and supply chain testing for food producers and public health agencies.